A Review of Modeling Approaches to Predict Drug Response in Clinical Oncology

被引:12
|
作者
Park, Kyungsoo [1 ]
机构
[1] Yonsei Univ, Coll Med, Dept Pharmacol, 50-1 Yonsei Ro, Seoul 03722, South Korea
关键词
Model-based approaches; drug development; drug treatment; chemotherapeutic drug; PROGRESSION-FREE SURVIVAL; SURROGATE END-POINT; PHARMACODYNAMIC MODEL; TUMOR-GROWTH; DISEASE PROGRESSION; CANCER-PATIENTS; CHEMOTHERAPY; SIZE; TIME; PHARMACOKINETICS;
D O I
10.3349/ymj.2017.58.1.1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Model-based approaches have emerged as important tools for quantitatively understanding temporal relationships between drug dose, concentration, and effect over the course of treatment, and have now become central to optimal drug development and tailored drug treatment. In oncology, the therapeutic index of a chemotherapeutic drug is typically narrow and a full dose-response relationship is not available, often because of treatment failure. Noting the benefits of model-based approaches and the low therapeutic index of oncology drugs, in recent years, modeling approaches have been increasingly used to streamline oncologic drug development through early identification and quantification of dose-response relationships. With this background, this report reviews publications that used model-based approaches to evaluate drug treatment outcome variables in oncology therapeutics, ranging from tumor size dynamics to tumor/biomarker time courses and survival response.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 50 条
  • [21] Profiles predict drug response
    Arnaud, C
    CHEMICAL & ENGINEERING NEWS, 2006, 84 (17) : 12 - 12
  • [22] Response - Examining the determinants of drug review times: Considering alternative approaches
    Olson, MK
    JOURNAL OF HEALTH POLITICS POLICY AND LAW, 2004, 29 (03) : 443 - 450
  • [23] Modeling approaches applied to the thermal response test: A critical review of the literature
    Rainieri, Sara
    Bozzoli, Fabio
    Pagliarini, Giorgio
    HVAC&R RESEARCH, 2011, 17 (06): : 977 - 990
  • [24] Synergistic approaches to clinical oncology biomarker discovery
    Belkowski, SM
    Polkovitch, D
    D'Andrea, MR
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2005, 5 (11) : 1047 - 1051
  • [25] APPROACHES TO INCREASE ONCOLOGY CLINICAL TRIALS ACCRUALS
    Merrill, Madeline
    Pandey, Shila
    Andronico, Jaclyn
    ONCOLOGY NURSING FORUM, 2024, 51 (02)
  • [26] A systematic review on drug interactions in oncology
    Riechelmann, Rachel P.
    Saad, Everardo D.
    CANCER INVESTIGATION, 2006, 24 (07) : 704 - 712
  • [27] Modeling Opportunities in Comparative Oncology for Drug Development
    Gordon, Ira K.
    Khanna, Chand
    ILAR JOURNAL, 2010, 51 (03) : 214 - 220
  • [28] Pancreatic cancer-derived organoids - a disease modeling tool to predict drug response
    Frappart, Pierre-Olivier
    Walter, Karolin
    Gout, Johann
    Beutel, Alica K.
    Morawe, Mareen
    Arnold, Frank
    Breunig, Markus
    Barth, Thomas F. E.
    Marienfeld, Ralf
    Schulte, Lucas
    Ettrich, Thomas
    Hackert, Thilo
    Svinarenko, Michael
    Roesler, Reinhild
    Wiese, Sebastian
    Wiese, Heike
    Perkhofer, Lukas
    Mueller, Martin
    Lechel, Andre
    Sainz, Bruno, Jr.
    Hermann, Patrick C.
    Seufferlein, Thomas
    Kleger, Alexander
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2020, 8 (05) : 594 - 606
  • [29] THE MODELING OF DRUG RESPONSE
    WHITING, B
    KELMAN, AW
    CLINICAL SCIENCE, 1980, 59 (05) : 311 - 315
  • [30] REVIEW OF APPROVED ONCOLOGY DRUG COMBINATION REGIMENS FROM A CLINICAL PHARMACOLOGY PERSPECTIVE.
    Cousin, C.
    Dai, I.
    Vugmeyster, Y.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 : S8 - S8